Effect of a trivalent vaccine against *Staphylococcus aureus* mastitis lymphocyte subpopulations, antibody production, and neutrophil phagocytosis

Jai-Wei Lee, Celia N. O’Brien, Albert J. Guidry, Max J. Paape, Kimberley A. Shafer-Weaver, X. Zhao

**Abstract**

The effect of a novel bovine mastitis trivalent vaccine, containing *Staphylococcus aureus* capsular polysaccharide type 5 (T5), 8 (T8), and 336 (T336), on lymphocyte subpopulations, antibody production, and neutrophil phagocytosis was evaluated. Twenty pregnant heifers were immunized with either the trivalent alone, trivalent emulsified in Freund’s incomplete adjuvant (FICA), trivalent in aluminum hydroxide, or adjuvant only (FICA). Immunization was done 30 d before the expected calving date followed by 2 boosts in a 2-week interval. Compared to FICA, serum antigen-specific immunoglobulin (IgG, and IgG2) were significantly increased in all the vaccinated groups before parturition and sustained until 3 wk postpartum. In comparison with the trivalent alone, formulation with either adjuvant enhanced production of IgG2, but not IgG1. Immune sera, which contained the highest amount of antibodies, slightly increased neutrophil phagocytosis to the 3 serotypes of killed *S. aureus*, but most of the differences were not significant due to large variation between the cows. The percentage of CD4+ lymphocyte was significantly higher in vaccinated groups than that of FICA 4 wk after the primary immunization. In comparison with FICA, cows inoculated with trivalent vaccine and adjuvants had an increased percentage of CD8+ lymphocytes at 2 time points, 2 wk before and after calving. Our results indicated that the whole cell trivalent vaccine, with or without adjuvants, is able to elicit antibody responses specific to the 3 capsular polysaccharide antigens. The increase of T8-specific IgG2 was more noticeable when the vaccine was emulsified with adjuvants.

**Résumé**

Un vaccin trivalent contre la mammite, contenant du matériel capsulaire polysaccharidique de *Staphylococcus aureus* type 5 (T5), 8 (T8) et 336 (T336), a été évalué pour ses effets sur les sous-populations lymphocytaires, la production d’anticorps et la phagocytose par les neutrophiles. Au total, 20 taures en gestation ont été immunisées avec soit le vaccin trivalent seul, le vaccin trivalent émulsifié dans de l’adjuvant incomplet de Freund (FICA), le vaccin trivalent dans de l’hydroxyde d’aluminium, ou l’adjuvant seulement (FICA). L’immunisation a été faite 30 j avant la date prévue de mise-bas, suivie de 2 injections de rappel dans un intervalle de 2 semaines. Comparativement au groupe témoin (FICA), les anticorps sériques spécifiques de type IgG1 et IgG2 étaient augmentés de manière significative chez tous les groupes d’animaux vaccinés avant la parturition et se sont maintenus jusqu’à 3 sem post-partum. Chez les animaux ayant reçu le vaccin combiné à l’un ou l’autre des adjuvants, la production d’IgG2, mais pas IgG1, était augmentée par rapport aux animaux n’ayant reçu que le vaccin sans adjuvant. Du sérum immunitaire contenant la plus grande quantité d’anticorps augmente légèrement la phagocytose par les neutrophiles des 3 sérotypes de *S. aureus* tués, mais la plupart des différences n’étaient pas significatives étant donné les variations marquées entre les vaches. Quatre semaines après la première immunisation, le pourcentage de lymphocytes CD4+ était significativement plus élevé dans les groupes d’animaux vaccinés comparativement au témoin FICA. En comparaison au groupe FICA, les vaches inoculées avec le vaccin trivalent et les adjuvants avaient un pourcentage plus élevé de lymphocytes CD8+ 2 sem avant et après le vêlage. Les résultats indiquent que le vaccin trivalent à base de cellules entières, avec ou sans adjuvants, est en mesure d’induire une réponse humorale spécifique aux 3 antigènes capsulaires polysaccharidiques. L’augmentation des IgG2 T8 spécifique était plus marquée lorsque le vaccin était émulsifié avec de l’adjuvant.

**(Traduit par Docteur Serge Messier)**

**Introduction**

*Staphylococcus aureus*, a contagious, gram-positive coccus, is the most frequently isolated pathogen from cases of mastitis (1,2). It accounts for 19% to 40% of intramammary infections (IMI) caused by major pathogens, usually subclinical, and is responsible for approximately 35% of economic loss due to mastitis (3). In Canada, it has been estimated that *S. aureus* infection may be present in as many as 90% of Ontario dairy farms (4). The cure rate of antibiotic treatment is low and the infection often becomes chronic. This could be attributed to the ability of *S. aureus* to locate intracellularly, including epithelial cells and macrophages, and survive antibiotic treatments (5–7). To date, effective prevention of *S. aureus* mastitis has not been achieved. Many efforts have been made to develop an...
effective vaccine to prevent *S. aureus* mastitis in the past decades. Numerous strategies, including immunization with killed bacteria cells or their virulent factors, have been practiced. However, these vaccines have shown poor responses or decreased prevalence and severity of mastitis only, but never efficiently prevented new IMIs caused by *S. aureus* (8,9).

Phagocytes, mostly neutrophils, are recruited to sites of infections and play a crucial role in bacterial clearance. *Staphylococcus aureus* is able to produce a capsular polysaccharide (CP) that masks recognition by phagocytes of antigenic cell wall components thus interfering with opsonization and phagocytosis of phagocytes. This makes *S. aureus* more resistant to the host immune system (7,10). It has been estimated that 94% to 100% of *S. aureus* isolated from mastitic cows are encapsulated (11). A total of 11 serotypes of *S. aureus* capsular polysaccharide (CP) have been identified (12). The result of serotyping *S. aureus* isolated from 178 dairy farms in the United States indicated that only 3 serotypes, T5 (18%), T8 (23%), and T336 (59%), were responsible for bovine *S. aureus* mastitis (13,14). In addition, the distribution of serotypes varies geographically. In comparison with the distribution in the United States, the percentage of serotypes from European samples were, T5 = 34%, T8 = 34%, T336 = 30%, and nontypable = 2% (14).

It has been suggested to use CP as the antigen for development of a successful vaccine against *S. aureus* (15). Theoretically, the interference of CP against phagocytosis can be circumvented by the production of CP-specific antibodies. However, CP is categorized as a T-cell independent (TI) antigen, which is poorly immunogenic (16). Indeed, injection of pure T5 CP failed to provoke an immune response in cows (17). Two subsets of T lymphocytes, T helper cells (CD4+), and T cytotoxic cells (CD8+), modulate immune responses in different ways. The CD4+ cells produce a variety of cytokines which lead to 2 different types of immune responses (Th1 and Th2) and antibody production from B cells (18). Interferon (IFN)-γ and interleukin (IL)-4 are the key cytokines promoting Th1 and Th2 type immunity, respectively. Generally speaking, Th2 type activates mainly antibody-mediated immune responses, including B cells proliferation and antibody secretion. On the other hand, Th1 type elicits both antibody-mediated (specific to IgG3) and cell-mediated immune responses. In cell-mediated immune responses, the cytotoxic activity of CD8+ cells is capable of eliminating altered self-cells, including intracellular pathogen-infected cells. Nevertheless, the T-cell independent (TI) nature of an antigen does not imply that T cells, or their cytokines, can not influence the immunogenicity of TI antigens. Using a CP-protein carrier conjugate has been shown to increase production of CP-specific antibody (17,19). Presumably, the conjugated protein antigens activate T cells through a classical T-cell dependent pathway, and the cytokines produced by activated T cells augment the anti-CP responses (20). Recently, the design of whole cell vaccines has been shown to elicit stronger immune responses than CP-protein conjugate (21). Therefore, a trivalent vaccine, containing killed whole cells from the 3 dominant serotypes of *S. aureus* in the United States, has been developed by scientists in United States Department of Agriculture (USDA).

In addition to the natural immunogenicity of an antigen, the efficacy of a vaccine is also determined by its adjuvant. Application of different adjuvants on a vaccine has been shown to elicit different types of immune responses (22), different levels of antibody production, and side effects (23). The most common adjuvants used in veterinary vaccines are aluminum hydroxide (ALUM) and Freund’s incomplete adjuvant (FICA). Both adjuvants are inexpensive and have a good safety record (24). However, due to the unique “T-cell independent” nature of CP antigens, the performance of these adjuvants when formulated into the trivalent vaccine needs to be investigated. In the present study, the trivalent vaccine was inoculated to pregnant heifers with or without adjuvants. The effects of different formulations were evaluated based on leukocyte-associated immune functions, including alteration of lymphocyte subpopulations, antigen-specific antibody secretion, and antibody-mediated phagocytosis. Since leukocytes, especially lymphocytes, play a pivotal role in the subsequent response after vaccination, the information might be useful to improve the efficacy of vaccines against *S. aureus* mastitis.

### Materials and methods

#### Preparation of vaccines

Three serotypes of *S. aureus*, T5, T8, and T336 (kindly supplied by Dr. A. Fattom, Nabi, Rockville, Maryland, USA), were grown in 10 mL of Columbia broth (T5 and T8) or tryptic soy broth (TSB) (T336) overnight at 37°C. Then 100 µL of T5 or T8 in Columbia broth were streaked on a Columbia agar plate (2%) and incubated overnight at 37°C. Bacteria were harvested by washing the microorganisms off the plate with phosphate buffered saline solution (PBBS). For T336, 100 µL of suspension was inoculated to TSB in a 250 mL flask. Bacteria were killed by 1% formalin overnight at room temperature. Killed bacteria were washed twice with PBBS and resuspended in 10 mL PBBS. The viability and encapsulation of bacteria were verified by plating a small volume of the suspension on a Columbia agar plate and capsular staining. The concentration of bacteria was determined by the optical density (OD) value. Equal amounts of each serotype were mixed and emulsified 1:1 with PBBS or the adjuvant, either FICA or ALUM. The final concentration of each serotype was 10^9/mL of vaccine.

#### Animals and immunization protocol

Twenty clinically healthy and pregnant heifers were selected and randomly assigned into 4 groups: (1) adjuvant FICA only (FICA) (n = 5); (2) trivalent only (T) (n = 6); (3) trivalent + FICA (T + F) (n = 4); and (4) trivalent + ALUM (T + A) (n = 5). Heifers received the primary immunization 1 mo (D0) before the expected calving date followed by 2 boosts with the same formulation in a 2-week interval, D14 and D28, respectively. The immunization was administered intramuscularly (2 mL) and in the area of supramammary lymph node (2 mL). Use of animals for this study was approved by the Beltsville Agriculture Research Center’s Animal Care and Use Committee.

#### Sampling of cows

Blood samples were collected from each heifer before immunization on D0, D14, and D28, as well as 3 times after calving, on C7, C14, and C21, respectively. Briefly, 100 mL of blood was drawn from the jugular vein into 2 50-mL syringes containing 6 mL of
40 mM ethylenediaminetetraacetic acid (EDTA) (Sigma, St. Louis, Missouri, USA). At each time point, blood samples were also taken from the tail vein, and serum was collected and stored at −20°C.

**Isolation of mononuclear cells**

Blood samples collected from the jugular vein were poured into 50 mL centrifuge tubes and centrifuged at 1800 × g for 30 min at 4°C. After centrifugation, 5 mL ofuffy coat was removed and added to another 50 mL tube containing 20 mL Hank’s balanced salt solution (HBSS) (GIBCO BRL, Gaithersburg, Maryland, USA). Thereafter, the mixture (25 mL) was carefully layered onto the surface of 12.5 mL ficoll-paque solution (1.077 g/mL; Amersham Biosciences, Piscataway, New Jersey, USA) in a 50 mL tube. Mononuclear cells were separated from red blood cells after centrifugation at 1200 × g, 19°C, for 30 min. The mononuclear cell band was removed and mixed with HBSS to the total volume of 45 mL, then centrifuged at 900 × g for 10 min, at 4°C. The pellet was resuspended in 10 mL of HBSS followed by enumeration of cells using a hemacytometer.

**Determination of lymphocyte subpopulations**

The determination of lymphocyte subpopulations was carried out as previously described (25). Briefly, isolated bovine mononuclear cells (2 × 10⁶) were incubated with one of the following mouse monoclonal antibodies (VMRD, Pullman, Washington, USA), including CD2 (αβ-T cells, 1:100), CD3 (T cell receptor, 1:100), CD4 (T helper cells, 1:160), CD8 (T cytotoxic/suppressor cells, 1:400), MHC II (1:200), B cells (1:100), and CD18 (negative control, 1:100), in 100 μL of FACS (500 mL PBSS, 10 mL FBS, 0.75 mL 20% sodium azide solution) in round bottom 96-well plates. The plates were kept at 4°C for 30 min. Then the plates were centrifuged at 1200 × g at 4°C for 5 min and washed twice with FACS, followed by the addition of 100 μL of fluorescein-isothiocynate (FITC)-conjugated goat secondary antibodies to mouse cells (Becton Dickinson Immunocytometry Systems, San Jose, California, USA). After 30 min of incubation at 4°C, the plates were washed 3 times. The cells were resuspended in 150 μL of the FACS solution and transferred to microtubes containing 350 μL of the FACS (final volume 500 μL). The percentage of each subpopulation was read by flow cytometry (Coulter Electronics, Hialeah, Florida, USA).

**Detection of antigen-specific antibodies in serum**

The antibody production was measured by enzyme-linked immunosorbent assays (ELISA), as previously described (26). Briefly, 96-well flat bottom plates (Immulon 4; Bynatech, Chantilly, Virginia, USA) were coated with purified T5, T8, or T336 in PBSS (1 μg/mL) and incubated overnight at 22°C. The coating solution was then

### Table I. Flow cytometric analysis of isolated peripheral blood mononuclear cells

<table>
<thead>
<tr>
<th>Receptor</th>
<th>Treatment</th>
<th>D0</th>
<th>D14</th>
<th>D28</th>
<th>C7</th>
<th>C14</th>
<th>C21</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD2</td>
<td>FICA</td>
<td>29.3 ± 5.7</td>
<td>27.2 ± 4.0&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>29.4 ± 4.1</td>
<td>29.4 ± 10.4</td>
<td>25.9 ± 3.9</td>
<td>27.6 ± 6.7</td>
</tr>
<tr>
<td></td>
<td>T</td>
<td>30.5 ± 5.2</td>
<td>23.6 ± 4.0&lt;sup&gt;b&lt;/sup&gt;</td>
<td>30.9 ± 4.9</td>
<td>23.2 ± 3.9</td>
<td>27.5 ± 4.0</td>
<td>23.4 ± 2.6</td>
</tr>
<tr>
<td></td>
<td>T + F</td>
<td>34.7 ± 5.2</td>
<td>37.0 ± 3.5&lt;sup&gt;a&lt;/sup&gt;</td>
<td>36.0 ± 4.2</td>
<td>33.3 ± 5.7</td>
<td>34.6 ± 5.7</td>
<td>30.5 ± 2.7</td>
</tr>
<tr>
<td></td>
<td>T + A</td>
<td>36.9 ± 5.2</td>
<td>38.6 ± 4.7&lt;sup&gt;a&lt;/sup&gt;</td>
<td>35.4 ± 4.2</td>
<td>32.1 ± 6.0</td>
<td>30.5 ± 5.7</td>
<td>36.6 ± 4.8</td>
</tr>
<tr>
<td>CD3</td>
<td>FICA</td>
<td>38.5 ± 5.5</td>
<td>37.2 ± 3.5</td>
<td>36.7 ± 6.0</td>
<td>39.2 ± 10.5</td>
<td>38.6 ± 13.0</td>
<td>35.6 ± 6.4</td>
</tr>
<tr>
<td></td>
<td>T</td>
<td>38.9 ± 5.5</td>
<td>30.9 ± 3.6</td>
<td>36.9 ± 3.2</td>
<td>32.4 ± 3.5</td>
<td>34.8 ± 6.0</td>
<td>31.1 ± 4.6</td>
</tr>
<tr>
<td></td>
<td>T + F</td>
<td>42.6 ± 7.5</td>
<td>36.2 ± 2.4</td>
<td>42.2 ± 4.1</td>
<td>41.6 ± 3.7</td>
<td>36.6 ± 5.1</td>
<td>35.7 ± 3.0</td>
</tr>
<tr>
<td></td>
<td>T + A</td>
<td>43.5 ± 3.7</td>
<td>42.0 ± 4.1</td>
<td>43.6 ± 6.4</td>
<td>36.5 ± 5.3</td>
<td>36.0 ± 4.0</td>
<td>42.5 ± 7.8</td>
</tr>
<tr>
<td>CD4</td>
<td>FICA</td>
<td>10.7 ± 3.9</td>
<td>15.1 ± 1.0</td>
<td>8.6 ± 3.0&lt;sup&gt;b&lt;/sup&gt;</td>
<td>8.7 ± 5.6</td>
<td>11.2 ± 5.3</td>
<td>15.4 ± 6.8</td>
</tr>
<tr>
<td></td>
<td>T</td>
<td>15.3 ± 3.9</td>
<td>15.6 ± 2.1</td>
<td>20.4 ± 3.3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>12.4 ± 2.5</td>
<td>16.7 ± 1.9</td>
<td>15.4 ± 1.7</td>
</tr>
<tr>
<td></td>
<td>T + F</td>
<td>20.1 ± 4.8</td>
<td>16.6 ± 1.2</td>
<td>17.7 ± 0.2&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>18.2 ± 1.2</td>
<td>18.0 ± 3.8</td>
<td>11.6 ± 3.0</td>
</tr>
<tr>
<td></td>
<td>T + A</td>
<td>11.9 ± 5.3</td>
<td>20.4 ± 6.0</td>
<td>20.4 ± 2.7&lt;sup&gt;a&lt;/sup&gt;</td>
<td>18.8 ± 3.7</td>
<td>12.6 ± 4.0</td>
<td>15.6 ± 7.3</td>
</tr>
<tr>
<td>CD8</td>
<td>FICA</td>
<td>8.3 ± 2.6</td>
<td>8.9 ± 2.3&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>8.1 ± 0.6</td>
<td>4.0 ± 2.7</td>
<td>7.6 ± 1.3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>8.2 ± 2.3</td>
</tr>
<tr>
<td></td>
<td>T</td>
<td>7.5 ± 1.0</td>
<td>5.6 ± 0.5&lt;sup&gt;b&lt;/sup&gt;</td>
<td>7.9 ± 1.0</td>
<td>5.6 ± 0.8</td>
<td>5.7 ± 0.9&lt;sup&gt;b&lt;/sup&gt;</td>
<td>8.0 ± 1.7</td>
</tr>
<tr>
<td></td>
<td>T + F</td>
<td>12.3 ± 3.5</td>
<td>11.2 ± 1.6&lt;sup&gt;a&lt;/sup&gt;</td>
<td>2.5 ± 4.4</td>
<td>10.4 ± 3.5</td>
<td>12.2 ± 1.6&lt;sup&gt;a&lt;/sup&gt;</td>
<td>7.0 ± 2.0</td>
</tr>
<tr>
<td></td>
<td>T + A</td>
<td>8.3 ± 1.8</td>
<td>12.1 ± 2.3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>9.9 ± 1.4</td>
<td>10.9 ± 3.2</td>
<td>12.0 ± 2.4&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>15.5 ± 3.1</td>
</tr>
<tr>
<td>MHC II</td>
<td>FICA</td>
<td>47.0 ± 9.6</td>
<td>56.2 ± 6.5&lt;sup&gt;a&lt;/sup&gt;</td>
<td>47.1 ± 12.9</td>
<td>37.2 ± 12.1</td>
<td>52.3 ± 9.3</td>
<td>58.4 ± 12.4</td>
</tr>
<tr>
<td></td>
<td>T</td>
<td>36.4 ± 9.2</td>
<td>48.3 ± 7.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>37.3 ± 9.5</td>
<td>44.5 ± 8.6</td>
<td>50.6 ± 9.9</td>
<td>59.1 ± 8.7</td>
</tr>
<tr>
<td></td>
<td>T + F</td>
<td>27.1 ± 5.5</td>
<td>27.1 ± 4.9&lt;sup&gt;a&lt;/sup&gt;</td>
<td>36.6 ± 4.3</td>
<td>36.7 ± 8.3</td>
<td>38.7 ± 6.0</td>
<td>37.0 ± 3.2</td>
</tr>
<tr>
<td></td>
<td>T + A</td>
<td>37.6 ± 8.7</td>
<td>37.9 ± 6.4&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>34.0 ± 8.4</td>
<td>47.6 ± 6.4</td>
<td>42.9 ± 11.1</td>
<td>37.4 ± 5.0</td>
</tr>
<tr>
<td>B cell</td>
<td>FICA</td>
<td>30.7 ± 8.4</td>
<td>38.0 ± 13.1</td>
<td>40.9 ± 10.3</td>
<td>25.8 ± 8.0</td>
<td>31.4 ± 7.5</td>
<td>45.0 ± 10.3</td>
</tr>
<tr>
<td></td>
<td>T</td>
<td>28.7 ± 9.8</td>
<td>35.4 ± 8.9</td>
<td>27.4 ± 7.7</td>
<td>30.8 ± 7.4</td>
<td>39.5 ± 10.7</td>
<td>51.1 ± 12.7</td>
</tr>
<tr>
<td></td>
<td>T + F</td>
<td>22.0 ± 5.7</td>
<td>24.7 ± 5.3</td>
<td>23.8 ± 3.4</td>
<td>24.0 ± 2.6</td>
<td>31.8 ± 3.0</td>
<td>26.6 ± 4.7</td>
</tr>
<tr>
<td></td>
<td>T + A</td>
<td>24.2 ± 5.4</td>
<td>26.6 ± 4.5</td>
<td>26.0 ± 5.1</td>
<td>31.8 ± 6.4</td>
<td>30.2 ± 6.0</td>
<td>25.8 ± 3.2</td>
</tr>
</tbody>
</table>

Values are mean ± s of the percentage of positive-stained cells and are compared with other treatments at each time point

<sup>a</sup> <sup>b</sup> Values with different superscripts are significantly different at P < 0.05

CD — ; FICA — Freud’s incomplete adjuvant; T — trivalent only; T + F — trivalent and Freud’s incomplete adjuvant; T + A — trivalent in aluminum hydroxide; MHC — major histocompatibility complex

The Canadian Journal of Veterinary Research 13
removed and the plates were blocked with 1% chicken serum albumin (Sigma Chemical Company) in PBSS at 22°C for 1 h. After washing the plates twice with PBSS-T (containing 0.05% Tween 20), samples diluted 500 times with PBSS-T were added into the wells. The plates were incubated at 4°C overnight. The plates were then washed 3 times and incubated with rabbit anti-bovine immunoglobulin (Ig)G1, IgG2, or IgM, diluted in PBSS containing 0.2% Tween 20 for 1 h at 37°C. After washing, alkaline-phosphatase labeled sheep anti-rabbit IgG (1:2000) (Kirkegaard and Perry, Gaithersburg, Maryland, USA) was added to the wells and incubated for another hour at 37°C. Substrate was added and the plates were read at OD 405 nm on a microtiter plate reader (Bio-Tek, Winooski, Vermont, USA).

**Neutrophil phagocytosis**

Blood neutrophils were isolated as previous described (27). The FITC-labeled bacteria (T5, T8, and T336) were slightly sonicated and $5 \times 10^7$ bacteria in 50 μL were added to each vial containing 50 μL of HBSS-diluted sera (collected on either D0 or C7) pooled from each group. The vials were covered by foil and gently shaken at 37°C for 30 min (opsonization). The concentration of isolated neutrophils was adjusted to $10 \times 10^6$/mL in HBSS and 250 μL of the suspension ($2.5 \times 10^6$ neutrophils) were added to each vial. All samples were incubated and rocked at 37°C for 30 min in dark. Thereafter, phagocytosis was ceased by adding 1 mL ice-cold NaCl (0.09%)-EDTA (0.04%). The fluorescent intensity was read by flow cytometry. The percentage of neutrophils with ingested FITC-labeled bacteria was determined after quenching extracellular fluorescence by adding 400 μL of 1% methylene blue. Samples containing neutrophils or bacteria only were used as controls.

**Statistical analysis**

For lymphocyte subpopulations and antibody responses, comparisons among treatments at each time point were made using mixed models analysis of variance (ANOVA) for repeated

---

**Figure 1.** Antigen specific immunoglobulin (Ig)G1 response in sera as determined by enzyme-linked immunosorbent assay (ELISA). Serum samples were diluted 1/500. Data are expressed as least square mean ± s.e. of the optical density (OD) values read at 405 nm. Treatments with different letters at same time point are significantly ($P < 0.05$) different.
measurements (SAS Institute, Cary, North Carolina, USA) (28). For the opsonic effect on neutrophil phagocytosis, comparisons were made between preimmune (D0) and immune (C7) sera for each treatment using the mixed procedure of SAS. Data of antibody response and phagocytosis were analyzed separately for each serotype. Data were presented as least squares means ± standard error of means (x̄). Differences were considered statistically significant when P < 0.05.

Results

Lymphocyte subpopulations

The effect of vaccination with different formulations on the expression of selected surface receptors of lymphocytes was presented in Table I. Expression of CD2, a marker of αβ-T lymphocytes, on D14 was significantly (P < 0.05) lowered in the group receiving trivalent only (T) in comparison with groups immunized with vaccines containing either one of the adjuvants (T + F or T + A). Vaccine formulations containing antigen with adjuvant also significantly increased the percentage of CD8+ lymphocytes at certain time points (T + F: D14 and C14; T + A: D14) when compared to trivalent only (P < 0.05). The groups receiving FICA only had a decreased percentage of CD4+ lymphocytes when compared to T and T + A. Expression of MHCII was the lowest in the group immunized with T + F. No significant differences among the treatments were observed on expression of CD3 (T cell receptor) and B cell receptor. Nonspecific binding of the negative control, antibody against CD18, remained low at all time points (data not shown).

Production of antigen-specific antibodies

In general, the vaccination significantly increased the amount of antigen-specific IgG1 and IgG2 in serum. The response of IgG1 against T5 and T8 was rapid (Figure 1). By D14, vaccinated groups showed an increase in IgG1 to at least 1 of the 3 antigens. However, responses of IgG1 to the 3 antigens were lower in cows immunized with
T + F after calving in comparison with T and T + A. Antigen administered with ALUM or FICA did not further augment antigen-specific IgG production in comparison with that of the trivalent only. On the other hand, both adjuvants had a positive effect on the production of IgG(Figure 2). The T + F and T + A, but not T, had a significantly increased (p < 0.05) IgG response to at least 1 of the 3 antigens around parturition when compared to FICA. In addition, the response of T8-specific IgG and IgG was stronger than those of T5- and T336-specific IgG and IgG. None of the vaccine formulations enhanced the production of antigen-specific IgM (data not shown).

**Neutrophil phagocytosis**

To investigate if the sera from vaccinated cows could increase the phagocytosis of *S. aureus* by blood neutrophils, neutrophils were isolated from healthy cows and incubated with FITC-labeled *S. aureus* opsonized by pooled sera collected on D0 and C7. In general, all immune sera, regardless of adjuvants, had an increased opsonic effect on neutrophils phagocytosis to killed *S. aureus*. However, most of the differences were not statistically significant. The C7 sera from cows immunized with T + F significantly increased the phagocytosis of T8 when compared to the sera from D0 (45.88 ± 12.33 versus 39.05% ± 12.33%, P < 0.05) (Figure 3).

**Discussion**

*Staphylococcus aureus* is the most frequently isolated pathogen from cases of bovine mastitis (1,2). Since the 3 dominant serotypes of *S. aureus* responsible for bovine mastitis in the United States were T5 (18%), T8 (23%), and T336 (59%) (13,14), a trivalent vaccine containing whole cells of these serotypes as antigens was developed to prevent intramammary infections induced by *S. aureus*. However, due to the complicated pathogenesis of *S. aureus* and the poor immunogenicity of CP, the immunogenicity of this trivalent vaccine needs to be enhanced. Therefore, the objective of this study was to investigate if the most common adjuvants, ALUM and FICA, could promote leukocyte-associated immune responses elicited by the vaccine. It has been indicated that cows are more susceptible to mastitis during the postpartum period (2 wk after calving), which might be attributed to the suppressed immune responses of lymphocytes (29). Thus, the primary vaccination and 2 boosts were given within a month prior to the expected calving date of each heifer. Theoretically, the maximal effect of vaccination could be reached during the postpartum period (2 wk after calving), which might be attributed to the suppressed immune responses of lymphocytes (29). Thus, the primary vaccination and 2 boosts were given within a month prior to the expected calving date of each heifer. Theoretically, the maximal effect of vaccination could be reached during the postpartum period by following this immunization protocol. This was supported by the production of IgG and IgG in serum. Nearly all the antigen-specific IgG and IgG reached the peak between D28 and C14. The IgM had a high preimmunization level for the antigens. However, vaccination did not have a positive effect on the production of IgM against *S. aureus* CP antigens, which was in agreement with an earlier study (26). Our data also showed that the response of T8-specific antibody was either stronger (higher OD value) or occurred earlier than T5 and T336. It has been suggested that the flaccid nature of T8 CP increases the exposure of the cell wall (26). Therefore, more protein antigens located on the cell wall of T8 *S. aureus* were available to augment the “conjugate” effect and subsequent humoral responses.

The vaccination did not significantly alter the subpopulations of lymphocytes. However, significant differences among formulations were observed sporadically at certain time points and might have biological relevance with the antibody secretion. For example, the trivalent vaccine, with or without adjuvant, increased the percentage of CD4+ lymphocytes on D28 when compared to the FICA. Cytokines produced by CD4+ cells are important to the maturation of B cells, which secrete antibodies. The increase of CD4+ cells coincided with the stronger response of IgG and IgG in serum observed on D28, indicating the requirement of CD4+ cells for IgG production. Moreover, increased number of CD4+ may be associated with the initiation of another type of cell-mediated immune responses, delayed-type hypersensitivity (DTH), which is effective in eliminating intracellular pathogens. Addition of adjuvants significantly increased the percentages of αβ-T lymphocytes (on D14) and CD8+ lymphocytes (on D14 and C14) in comparison with cows immunized with the trivalent only. The percentage of αβ-T lymphocytes represents the subpopulations of both CD4+ and CD8+ lymphocytes. The CD8+ cells are associated with the cytotoxic activity of T lymphocytes, which is triggered in Th1 type immune responses. The increased percentage of CD8+ cells suggested that formulation with adjuvants influenced a Th1 response. This is supported by the result that IgG production, an indicator of Th1 type responses, was significantly increased in cows receiving vaccines emulsified with adjuvants. The expression of MHCII receptor was...
significantly lower in groups immunized with trivalent vaccines containing adjuvants. Although MHCII receptors are not required for the presentation of CP antigens, uptake of TI antigens has been shown to inhibit MHCII-restricted antigen presentation in macrophages (30). It is possible that formulated adjuvants increased the ingestion of CP antigens by antigen-presenting mononuclear cells, and this in turn decreased the expression of MHCII receptors. Further investigations will be required to verify this hypothesis.

Comparing opsonic effects of preimmunization sera and sera from C7 revealed that opsonization was slightly enhanced after vaccination. However, only the sera collected from cows immunized with T + F on C7 significantly increased the phagocytosis of neutrophils to T8 S. aureus. Although the overall production of antigen-specific antibodies was generally increased in the serum of cows immunized with vaccines, IgG2, the most effective opsonin promoting neutrophils phagocytosis (14,32), may not be produced sufficiently to enhance phagocytosis. It has been shown that a minimum amount of specific IgG2 antibody is required for promoting phagocytosis (26). Although production of IgG2 was increased in vaccinated cows, the amount was still much lower than that of IgG1, which is not opsonic for bovine neutrophil phagocytosis. In fact, IgG2 was reported to inhibit bovine neutrophil phagocytosis (27). Both ALUM and FICA have been shown to stimulate mainly Th2 type responses (33). Therefore, it was not surprising to see the limited effect of these vaccines on production of IgG2.

Taken together, immunization of the novel trivalent vaccine, with or without adjuvants, increased the amount of antigen-specific antibodies in serum. However, their effects on other parameters, including alteration of lymphocyte subsets and neutrophil phagocytosis were minimal. Neither ALUM nor FICA induced a persistent enhancement on these parameters. The failure could be due to the Th2 type nature of both adjuvants. Nevertheless, adjuvants known to induce Th1 type immune responses, such as Freund’s complete adjuvant (FCA), usually have undesirable side effects, such as tissue damage (34). Further research will be required to design an optimal formulation for the trivalent vaccine to prevent S. aureus mastitis.

References


